Specialist Interest in Cystic Fibrosis
As of 2010, there are more than 1,200 people in Ireland living with Cystic Fibrosis (CF), making it a key concern for the country’s medical sector. Statistics show that the Republic of Ireland has:
- the highest CF incidence rate in the world, at 2.98 per 10,000 people
- the highest CF carrier rate in the world, with 1 in 19 individuals classed as carriers
- an incidence of CF nearly four times the average rate in other EU countries and the USA
- approximately 35‐40 children (one in 1,461) born with CF each year (for some other European populations this stands at 1 in 3,500 births).
In addition, a recent World Health Organisation (WHO) publication lists Ireland as the country with the highest known incidence of CF.
Cystic Fibrosis Ireland – Specialist Expertise
As a result of the high incidence of patients with CF in Ireland, Java Clinical Research has developed extensive experience in the conduct of clinical trials in this patient population.
Through our collaboration with the key Irish CF Investigators we have developed excellent working relationships with all of the CF Specialist Units in Ireland, a factor which we consider critical in ensuring that recruitment targets and study timelines are achieved as specified. This has enabled us to successfully conduct studies in both adult and paediatric CF patient populations.
Studies with CF Opinion Leaders
Java has conducted studies with key CF opinion leaders and their specialist teams in the United Kingdom. In addition, we have led site feasibility assessments and met with lead CF investigators in Germany. This has enabled us to build a database of investigational sites suitable for participation in CF clinical trials both within, and outside of, Ireland.
If you are considering running a clinical trial on Cystic Fibrosis, we have a unique, comprehensive service offering which can be designed to meet your needs. We look forward to your enquiry.
To learn more about emerging drug therapies for the treatment of Cystic Fibrosis take a look at this information piece.